Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gracell Reports Positive Data from Trial of BCMA/CD19 FasTCAR-T in Multiple Myeloma

publication date: Jun 5, 2023

Shanghai Gracell Biotech reported its dual-targeting BCMA/CD19 FasTCAR-T candidate showed efficacy in heavily pre-treated patients with relapsed/refractory multiple myeloma. The median duration of response was 37 months in patients who had previously received a median of five therapy rounds, and the median progression free survival was 38 months. FasTCAR-T, Gracell’s CAR-T technology, produces an autologous CAR-T treatment overnight instead of nearly a month. The single-arm, investigator-initiated trial enrolled 29 RRMM patients. Gracell released the data for GC012F, its lead candidate, in an abstract at the ASCO meeting. More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here